Online citations, reference lists, and bibliographies.
← Back to Search

Guidelines For The Preclinical In Vivo Evaluation Of Pharmacological Active Drugs For ALS/MND: Report On The 142nd ENMC International Workshop

A. Ludolph, C. Bendotti, E. Blaugrund, B. Hengerer, J. Loeffler, J. Martin, V. Meininger, T. Meyer, Saliha Moussaoui, W. Robberecht, S. Scott, V. Silani, L. H. van den Berg, ENMC GROUP FOR THE ESTABLISHMENT OF GUIDELINES FOR
Published 2007 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
A transgenic animal model for anterior horn cell loss was established in 1994. This model is based on the insertion of a high copy number of disease‐causing human Cu/Zn SOD mutations into the intact mouse genome. It serves to establish hypotheses for the pathogenesis of anterior horn cell death, but also to test potential pharmacological approaches to therapy in human ALS. Today, more than 100 – published and unpublished – compounds have been tested in this animal model, a large part of them being reported as successful. However, it proved to be difficult to translate these therapeutic successes in the animal model into human trials. Also, a number of disease‐modifying strategies were difficult to reproduce, even by the same group. On the other hand, the step from mice to men means a huge investment for the sponsors of clinical trials and the scientific community. Therefore, establishment of standard methods for drug testing in ALS models is mandatory. In this workshop, clinical and preclinical researchers established in the field of ALS/MND met in Holland in March 2006 in order to establish guidelines for the community for drug testing in mouse models.
This paper references
Neuronal expression of an ALS-linked mutant dynactin P150 glued in mice causes motor neuron disease
FM Laird (2005)
10.1002/ana.10374
Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS
D. Drachman (2002)
Age-dependent changes in MRI of motor brainstem nuclei in a mouse model of ALS
F Angenstein (2004)
10.1056/NEJM199403033300901
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
G. Bensimon (1994)
10.1038/nrn1971
Molecular biology of amyotrophic lateral sclerosis: insights from genetics
P. Pasinelli (2006)
power and interpretation of studies in the standard murine model of amyotrophic lateral sclerosis
Scott S Design (2006)
10.1038/6568
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
P. Klivényi (1999)
Cortical neurons: their role in movement
G C Philips
10.1007/s00415-004-0481-5
Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model
S. Waibel (2004)
10.1126/SCIENCE.8209258
Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.
M. Gurney (1994)
10.1073/PNAS.0402026101
Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model.
L. Dupuis (2004)
10.1002/mus.20542
Oxidative stress and antioxidant enzyme upregulation in SOD1‐G93A mouse skeletal muscle
D. J. Mahoney (2006)
10.1016/J.TIPS.2006.03.009
Targets in ALS: designing multidrug therapies.
M. T. Carrì (2006)
Design, power and interpretation of studies in the standard murine model of amyotrophic lateral sclerosis
S. Scott (2006)
10.1016/S0140-6736(96)91680-3
Dose-ranging study of riluzole in amyotrophic lateral sclerosis
Amyotrophic Lateral SclerosisRiluzole Study Group (1996)
Oxidative stress and antioxidant enzyme up-regulation in SOD1-G93A mouse skeletal muscle
DJ Mahoney (2006)
10.1002/ana.10554
A randomized sequential trial of creatine in amyotrophic lateral sclerosis
Geert Jan Groeneveld (2003)
10.1016/j.expneurol.2006.04.007
In vivo quantification of spinal and bulbar motor neuron degeneration in the G93A-SOD1 transgenic mouse model of ALS by T2 relaxation time and apparent diffusion coefficient
H. G. Niessen (2006)
10.1097/00001756-200206120-00018
Minocycline delays disease onset and mortality in a transgenic model of ALS
L. Van Den Bosch (2002)
Copaxone treatment in a mouse model of ALS: effect of gender and genetic background
B Schwalenstöcker (2004)
10.1126/science.1123511
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
S. Boillée (2006)
10.1016/0022-510X(95)00067-C
Solutions to old problems in the quantitation of the central nervous system
B. Pakkenberg (1995)
10.1038/362059a0
Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
D. R. Rosen (1993)
10.1073/pnas.0530191100
Therapeutic vaccine for acute and chronic motor neuron diseases: Implications for amyotrophic lateral sclerosis
D. Angelov (2003)
10.1111/j.1471-4159.2005.03024.x
Integrative role of cPLA2 with COX‐2 and the effect of non‐steriodal anti‐inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis
M. Kiaei (2005)
A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis
C Desnuelle (2001)
10.1212/WNL.65.6.972-a
Physical activity and the association with sporadic ALS
A. Ascherio (2005)
10.1080/146608201300079364
A double-blind, placebo-controlled randomized clinical trial of α-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis
C. Desnuelle (2001)
10.1016/J.MOLBRAINRES.2004.07.002
Effect of transgene copy number on survival in the G93A SOD1 transgenic mouse model of ALS.
G. Alexander (2004)
10.1016/S0306-4522(99)00512-6
Repeated stimuli for axonal growth causes motoneuron death in adult rats: the effect of botulinum toxin followed by partial denervation
C. M. White (1999)
10.1097/00001756-200410050-00026
Age-dependent changes in MRI of motor brain stem nuclei in a mouse model of ALS
F. Angenstein (2004)
10.1016/j.jns.2005.02.006
Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS
T. Heiman-Patterson (2005)
10.1016/J.MOLMED.2004.06.009
Lessons from models of SOD1-linked familial ALS.
C. Bendotti (2004)
10.1080/14660820510012022
Benefit of tianeptine and morphine in a transgenic model of familial amyotrophic lateral sclerosis
M. Chritin (2006)
10.1038/nm1021
Treatment with arimoclomol, a coinducer of heat shock proteins, delays disease progression in ALS mice
D. Kieran (2004)
10.1016/S1471-4914(02)02373-0
Dual action of glatiramer acetate (Cop-1) in the treatment of CNS autoimmune and neurodegenerative disorders.
J. Kipnis (2002)
10.1016/J.BBADIS.2006.03.006
Transgenic mouse models of amyotrophic lateral sclerosis.
J. Julien (2006)
10.1002/ANA.410390203
Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis
M. Gurney (1996)
10.1007/s00702-004-0220-1
High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study
M. Graf (2004)
10.1002/ana.20903
Trial of celecoxib in amyotrophic lateral sclerosis
M. Cudkowicz (2006)
10.1002/ana.20316
Vitamin E intake and risk of amyotrophic lateral sclerosis
A. Ascherio (2005)
10.1080/17482960600783456
Erythropoietin does not preserve motor neurons in a mouse model of familial ALS
G. Grignaschi (2007)
10.1002/ana.10561
Of mice and men: Reconciling preclinical ALS mouse studies and human clinical trials
J. Rothstein (2003)
10.1212/WNL.56.7.843
Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis
R. Miller (2001)



This paper is referenced by
INVESTIGATION OF THE CYTOPROTECTIVE EFFECTS OF SONIC HEDGEHOG IN CELLULAR AND ANIMAL MODELS OF AMYOTROPHIC LATERAL SCLEROSIS
Randy Peterson (2012)
10.1016/j.pneurobio.2008.01.001
Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS
Bradley J. Turner (2008)
10.1007/s12035-013-8573-9
Advances in Cellular Models to Explore the Pathophysiology of Amyotrophic Lateral Sclerosis
C. Veyrat-Durebex (2013)
10.1177/1756285609336399
Review: Evidence-based drug treatment in amyotrophic lateral sclerosis and upcoming clinical trials
Albert Christian Ludolph (2009)
10.1002/prp2.636
Effects of RAGE inhibition on the progression of the disease in hSOD1G93A ALS mice
Liping Liu (2020)
10.1371/journal.pone.0046185
c-Abl Inhibition Delays Motor Neuron Degeneration in the G93A Mouse, an Animal Model of Amyotrophic Lateral Sclerosis
Ryu Katsumata (2012)
10.3389/fnins.2017.00451
Axonal Degeneration during Aging and Its Functional Role in Neurodegenerative Disorders
Natalia A Salvadores (2017)
10.1007/s12017-014-8317-7
Dietary Lipid Unsaturation Influences Survival and Oxidative Modifications of an Amyotrophic Lateral Sclerosis Model in a Gender-Specific Manner
D. Cacabelos (2014)
10.2174/187152710793237377
Phenotypic screening strategies for neurodegenerative diseases: a pathway to discover novel drug candidates and potential disease targets or mechanisms.
R. Pruss (2010)
10.1101/2019.12.27.889246
A non-invasive digital biomarker for the detection of rest disturbances in the SOD1G93A mouse model of ALS
E. Golini (2019)
Amyotrophic lateral sclerosis : mortality and predictors of survival
P. Gordon (2012)
10.1111/j.1471-4159.2012.07928.x
CSF biomarking for diagnosis and treatment assessment in neurodegeneration
J. Hardy (2012)
The Neuroprotective and Therapeutic Effects of Anthocyanins and Their Metabolites In Vitro and in a Mouse Model of Amyotrophic Lateral Sclerosis
A. Winter (2016)
10.1016/S1474-4422(08)70293-X
Biomarkers in amyotrophic lateral sclerosis
M. Turner (2009)
10.7150/ijbs.38487
Nicotinamide Riboside Enhances Mitochondrial Proteostasis and Adult Neurogenesis through Activation of Mitochondrial Unfolded Protein Response Signaling in the Brain of ALS SOD1G93A Mice
Q. Zhou (2020)
10.3109/17482960902803432
Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double- blind, randomized, multicentre, placebo-controlled trial
V. Meininger (2009)
10.3109/17482960903545334
Guidelines for preclinical animal research in ALS/MND: A consensus meeting
A. Ludolph (2010)
10.1093/bmb/ldp049
Motor neuron disease: systematic reviews of treatment for ALS and SMA.
R. Orrell (2010)
10.1016/j.jns.2007.06.010
Stem cell transplantation in Multiple Sclerosis: Safety and Ethics
V. Silani (2008)
10.1371/journal.pone.0135570
Guanabenz Treatment Accelerates Disease in a Mutant SOD1 Mouse Model of ALS
F. Vieira (2015)
10.14264/uql.2015.156
The role of complement system in amyotrophic lateral sclerosis
J. D. Lee (2014)
10.1073/pnas.1213960109
Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis
Rachel Tesla (2012)
10.1002/mus.24237
Presymptomatic electrophysiological tests predict clinical onset and survival in SOD1G93A ALS mice
R. Mancuso (2014)
The Role Of The RNA-Binding Protein Rho Guanine Nucleotide Exchange Factor In The Cellular Stress Response
Kevin K W Cheung (2014)
10.1038/s41418-019-0422-6
LanCL1 promotes motor neuron survival and extends the lifespan of amyotrophic lateral sclerosis mice
Honglin Tan (2019)
10.1016/j.nbd.2013.10.010
Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation
M. Peviani (2014)
10.1016/j.neuropharm.2011.10.009
dl-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis
X. Feng (2012)
10.4161/auto.28784
Pathogenic role of BECN1/Beclin 1 in the development of amyotrophic lateral sclerosis
Melissa Nassif (2014)
10.1016/B978-0-12-373861-5.00019-9
Translational Research in ALS
J. Montes (2008)
10.1186/s13024-016-0122-3
ZNStress: a high-throughput drug screening protocol for identification of compounds modulating neuronal stress in the transgenic mutant sod1G93R zebrafish model of amyotrophic lateral sclerosis
A. McGown (2016)
[Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine].
J. Gamez (2008)
Electrophysiological biomarkers for the study of new therapeutic strategies for motoneuron disease
R. Mancuso (2014)
See more
Semantic Scholar Logo Some data provided by SemanticScholar